AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) – Equities researchers at B. Riley issued their FY2022 earnings per share (EPS) estimates for AMAG Pharmaceuticals in a research report issued on Tuesday. B. Riley analyst D. Buck expects that the specialty pharmaceutical company will post earnings per share of $1.78 for the year. B. Riley has a “Hold” rating and a $16.00 price objective on the stock.
AMAG Pharmaceuticals (NASDAQ:AMAG) last issued its quarterly earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported $1.57 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $1.61. AMAG Pharmaceuticals had a negative return on equity of 0.64% and a negative net margin of 35.35%.
Shares of AMAG Pharmaceuticals (NASDAQ:AMAG) traded down $0.70 on Wednesday, hitting $13.25. The stock had a trading volume of 797,989 shares, compared to its average volume of 825,392. The company has a quick ratio of 1.48, a current ratio of 1.59 and a debt-to-equity ratio of 0.94. AMAG Pharmaceuticals has a twelve month low of $11.93 and a twelve month high of $25.20. The firm has a market capitalization of $467.57, a price-to-earnings ratio of -2.18 and a beta of 0.79.
Institutional investors have recently made changes to their positions in the business. Hartford Investment Management Co. bought a new stake in shares of AMAG Pharmaceuticals in the third quarter worth about $186,000. 361 Capital LLC bought a new stake in shares of AMAG Pharmaceuticals in the third quarter worth about $197,000. Cubist Systematic Strategies LLC bought a new stake in shares of AMAG Pharmaceuticals in the third quarter worth about $197,000. Aperio Group LLC bought a new stake in shares of AMAG Pharmaceuticals in the third quarter worth about $198,000. Finally, Municipal Employees Retirement System of Michigan increased its holdings in shares of AMAG Pharmaceuticals by 58.8% in the third quarter. Municipal Employees Retirement System of Michigan now owns 13,150 shares of the specialty pharmaceutical company’s stock worth $243,000 after acquiring an additional 4,870 shares in the last quarter.
ILLEGAL ACTIVITY NOTICE: “Equities Analysts Offer Predictions for AMAG Pharmaceuticals, Inc.’s FY2022 Earnings (AMAG)” was reported by Week Herald and is the sole property of of Week Herald. If you are reading this report on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this report can be read at https://weekherald.com/2018/01/19/equities-analysts-offer-predictions-for-amag-pharmaceuticals-inc-s-fy2022-earnings-amag.html.
About AMAG Pharmaceuticals
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.